C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
167/211, 260/251
C07D 401/00 (2006.01) C07D 213/40 (2006.01) C07D 215/18 (2006.01) C07D 215/227 (2006.01) C07D 215/28 (2006.01) C07D 215/48 (2006.01) C07D 215/54 (2006.01) C07D 401/04 (2006.01) C07D 405/04 (2006.01) C07D 407/04 (2006.01) C07D 409/04 (2006.01) C07D 413/04 (2006.01) C07D 417/04 (2006.01)
Patent
CA 1253497
9387-64 Abstract of the Disclosure A quinolone inotropic agent of the formula:- Image --- (I) or a pharmaceutically acceptable salt thereof, wherein "Het" is an optionally substituted 5- or 6-membered monocyclic aromatic heterocyclic group attached by a carbon atom to the 5-, 6-, 7- or 8- position of said quinolone; R, which is attached to the 5-, 6-, 7- or 8- position, is hydrogen, C1-C4 alkyl; C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulphinyl, C1-C4 alkylsulphonyl, halo, CF3, hydroxy, hydroxymethyl, or cyano; R1 is hydrogen, cyano, (C1-C4 alkoxy)- carbonyl, C1-C4 alkyl, nitro, halo, -NR3R4 or -CONR3R4 where R3 and R4 are each independently H or C1-C4 alkyl or together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocyclic group optionally containing a further heteroatom or group selected from O, S and N-R5 where R5 is H or C1-C4 alkyl; R2 is H, C1-C4 alkyl, or 2-hydroxyethyl; Y is H or C1-C4 alkyl; and the dotted line between the 3- and 4- positions represents an optional bond, these novel compounds and their pharmaceutically acceptable salts being cardiac stimulants useful in the curative or prophylactic treatment of cardiac conditions, in particular heart failure. PLC 391/A (SPC 6780/A)
470605
Campbell Simon F.
Roberts David A.
Pfizer Corporation
Smart & Biggar
LandOfFree
Heterocyclic-substituted quinolone inotropic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic-substituted quinolone inotropic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic-substituted quinolone inotropic agents will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1175477